For APPs & Nurses

The recommended dose of RYBREVANT® is based on baseline body weight and administered as an intravenous infusion after dilution.1

RYBREVANT® + LAZCLUZE™

Recommended dosing schedule for RYBREVANT® + LAZCLUZE™1,2

RYBREVANT® (amivantamab) and LAZCLUZE™ dosing scheduleRYBREVANT® (amivantamab) and LAZCLUZE™ dosing timeline

With LAZCLUZE™

When given in combination with LAZCLUZE™, administer LAZCLUZE™ any time before RYBREVANT® when given on the same day.

Refer to the full LAZCLUZE™ Prescribing Information for recommended LAZCLUZE™ dosing information.

In the MARIPOSA trial, infusion times decreased over time with RYBREVANT®3

Clinical trial median infusion times by hours*

RYBREVANT® (amivantamab) infusion times in the Papillon trial over timeRYBREVANT® median infusion times in the Mariposa trial

Total infusion time is approximately 4 to 6 hours for Day 1 and 6 to 8 hours for Day 2. Subsequent infusion time is approximately 2 hours.1

*Data reflect results from 2-week dosing in the MARIPOSA study.

RYBREVANT® + Chemotherapy

Recommended dosing schedule for RYBREVANT® + chemotherapy1

RYBREVANT® (amivantamab) and chemotherapy dosing scheduleRYBREVANT® (amivantamab) and chemotherapy dosing schedule

Refer to the full Prescribing Information for pemetrexed and carboplatin for the respective dosing information.

For additional dosage and administration guidance for RYBREVANT® (including as a single agent), please see the full Prescribing Information.

*This refers only to RYBREVANT® and pemetrexed. Carboplatin should only be taken for up to 12 weeks.1

In the PAPILLON trial, infusion times decreased over time with RYBREVANT®3

Clinical trial median infusion times by hours*

RYBREVANT® median infusion times in the Papillon trialRYBREVANT® (amivantamab) infusion times in the Papillon trial over time

Total infusion time is approximately 4 to 6 hours for Day 1 and 6 to 8 hours for Day 2. Day 2 chair time is longer because of increased dose from Day 1. Subsequent infusion time is approximately 2 hours.1

*Data reflect results from 3-week dosing in the PAPILLON study.

AUC, area under the curve; Q2W, once every 2 weeks; Q3W, once every 3 weeks.

References:

  1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. LAZCLUZE™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Data on file. Horsham, PA: Janssen Biotech, Inc.